Other Events ·
Tempest Therapeutics entered into an exclusive collaboration, option, and license agreement with Heibei Senlang…
TPSTTempest Therapeutics, Inc.
Tempest Therapeutics entered into an exclusive collaboration, option, and license agreement with Heibei Senlang Biotechnology Co., Ltd. on September 14, 2026. The deal grants Tempest a four-month exclusive option to acquire worldwide rights (excluding Greater China) to develop and commercialize Senlang’s in vivo CAR-T technology. Exercising the option requires an approximate $447,000 fee. A definitive license would impose escalating annual maintenance fees from $10 million to $14 million over three years, a 6% royalty on net sales, and sublicense revenue sharing. Tempest must use commercially reasonable efforts to develop at least one product and meet specific IND-filing or business-development milestones. The company operates in the biotechnology industry, developing in vivo CAR-T therapies for cancer and autoimmune diseases.